Y-Intercept (HK)’s Neurocrine Biosciences NBIX Stock Holding History

Y-Intercept (HK)’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-44,837	Closed	-$6.36M	–	1888
2025 Q4	$6.36M	Buy	44,837 +33,654	+301%	+$4.88M	0.14%	155
2025 Q3	$1.57M	Buy	+11,183	New	+$1.52M	0.04%	749
2025 Q2	–	Sell	-13,202	Closed	-$1.46M	–	1886
2025 Q1	$1.46M	Buy	+13,202	New	+$1.67M	0.1%	268
2024 Q4	–	Sell	-31,781	Closed	-$3.66M	–	1498
2024 Q3	$3.66M	Buy	+31,781	New	+$4.36M	0.22%	82
2024 Q2	–	Sell	-3,891	Closed	-$537K	–	1735
2024 Q1	$537K	Buy	+3,891	New	+$531K	0.04%	676
2023 Q3	–	Sell	-3,937	Closed	-$371K	–	1409
2023 Q2	$371K	Sell	3,937 -2,279	-37%	-$223K	0.04%	691
2023 Q1	$629K	Buy	6,216 +96	+2%	+$9.99K	0.07%	416
2022 Q4	$731K	Buy	6,120 +2,475	+68%	+$290K	0.11%	299
2022 Q3	$387K	Buy	+3,645	New	+$370K	0.04%	626
2021 Q4	–	Sell	-2,738	Closed	-$263K	–	779
2021 Q3	$263K	Buy	+2,738	New	+$259K	0.05%	505

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Y-Intercept (HK)'s NBIX Position: Q1 2026 in Review

Y-Intercept (HK) sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 44,837 shares — an estimated $6.36M sold.

Y-Intercept (HK) first reported a position in NBIX in Q3 2021 and held it in 10 quarters. The position peaked at $6.36M in Q4 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Y-Intercept (HK) reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
Y-Intercept (HK) sold 44,837 Neurocrine Biosciences shares in Q1 2026, an estimated $6.36M.
Y-Intercept (HK) first reported a position in Neurocrine Biosciences in Q3 2021 and held it in 10 quarters.
Y-Intercept (HK)'s Neurocrine Biosciences position peaked at $6.36M in Q4 2025.
694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Y-Intercept (HK)'s 13F filing for Q1 2026, filed 27 Apr 2026.